Metformin Al (Metformin Hydrochloride)

• Metformin Al is a biguanide that lowers elevated blood glucose in disorders of glucose metabolism.
• Type 2 diabetes mellitus: improves glycemic control by reducing hepatic glucose output and enhancing peripheral insulin sensitivity.
• Prediabetes: helps delay progression to diabetes by modestly lowering fasting glucose levels.
• Polycystic ovary syndrome (off‑label): may improve insulin resistance and menstrual regularity in affected women.

• Metformin Hydrochloride primarily inhibits mitochondrial respiratory‑chain complex I, decreasing hepatic gluconeogenesis. It also reduces intestinal glucose absorption and increases peripheral tissue uptake of glucose by enhancing insulin receptor signaling, leading to lower fasting and post‑prandial blood glucose concentrations.

Metformin Al may cause a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: frequent loose stools, especially at treatment initiation.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: transient alteration of taste perception.
• Loss of appetite: reduced desire to eat.
• Vitamin B12 deficiency: gradual decrease with long‑term use.

Serious or Rare Side Effects

• Lactic acidosis: life‑threatening accumulation of lactate, especially in renal impairment.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Hepatotoxicity: rare liver enzyme elevations.
• Hypoglycemia: when combined with other glucose‑lowering agents.
• Pancreatitis: very uncommon inflammation of the pancreas.

• Metformin Al requires careful consideration of patient‑specific factors before and during therapy.
• Renal function: assess eGFR before initiating and monitor periodically.
• Liver disease: use with caution in patients with hepatic impairment.
• Alcohol consumption: avoid excessive intake due to increased lactic acidosis risk.
• Pregnancy: discuss potential risks with a healthcare provider; safety category is unknown.
• Elderly patients: monitor renal function and hydration status closely.
• Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Metformin Al can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure; discontinue metformin before imaging.
• Cimetidine: can increase metformin plasma concentrations.
• Alcohol: potentiates risk of lactic acidosis.
• Renin‑angiotensin system inhibitors: may affect renal function and metformin clearance.
• Nucleoside reverse transcriptase inhibitors: increase metformin levels.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms.
• Thiazide diuretics: can raise blood glucose.
• Corticosteroids: may reduce metformin’s glucose‑lowering effect.
• Sulfonylureas: increase risk of hypoglycemia when combined.
• GLP‑1 receptor agonists: additive glucose‑lowering effect requiring monitoring.